

Neil E Kay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5244265/publications.pdf>

Version: 2024-02-01

368
papers

14,914
citations

18436

62
h-index

20900

115
g-index

369
all docs

369
docs citations

369
times ranked

12380
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	3.3	10
2	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	2.0	13
3	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	3.2	11
4	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2022, 40, 302-306.	0.8	2
5	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	2.8	9
6	CLL update 2022: A continuing evolution in care. <i>Blood Reviews</i> , 2022, 54, 100930.	2.8	24
7	Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. <i>Blood</i> , 2022, 139, 2252-2256.	0.6	7
8	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	0.6	53
9	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	3.3	1
10	Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	0.6	93
11	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. <i>Leukemia</i> , 2022, 36, 1635-1645.	3.3	12
12	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
13	B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	2
14	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021, 35, 239-244.	3.3	21
15	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155.	0.8	32
16	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
17	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
18	Chronic lymphocytic leukemia B-cell-derived TNF α impairs bone marrow myelopoiesis. <i>IScience</i> , 2021, 24, 101994.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	6.9	31
20	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). <i>Vaccine</i> , 2021, 39, 1122-1130.	1.7	26
21	Upregulation of AXL and β -catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. <i>Blood Cancer Journal</i> , 2021, 11, 37.	2.8	1
22	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
23	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 47.	2.8	7
24	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021, 29, 1529-1540.	3.7	43
25	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021, 138, 149-159.	0.6	20
26	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	0.6	16
27	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 8318.	1.6	3
28	The prognostic significance of $\text{del}6q23$ in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E203-E206.	2.0	1
29	SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. <i>Blood Cancer Journal</i> , 2021, 11, 93.	2.8	9
30	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86.	2.8	14
31	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	0.8	266
32	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	1.6	14
33	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	0.6	16
34	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140.	2.8	6
35	Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?. <i>Leukemia</i> , 2021, 35, 3364-3370.	3.3	4
36	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021, 138, 906-906.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	1.1	1
38	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021, 138, 2777-2777.	0.6	0
39	Early intervention in asymptomatic chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 92-103.	0.3	6
40	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	1.7	64
41	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60.	2.0	9
42	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	1.9	15
43	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.4	40
44	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1581-1589.	0.6	4
45	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020, 29, 2761-2774.	1.4	6
46	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	0.4	2
47	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. <i>Leukemia</i> , 2020, 34, 1979-1983.	3.3	4
48	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399.	1.3	36
49	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020, 95, 906-917.	2.0	17
50	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , 2020, 4, 1407-1418.	2.5	12
51	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
52	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	0.6	15
53	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
54	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020, 105, 2675-2678.	1.7	17

#	ARTICLE	IF	CITATIONS
55	Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
56	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
57	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
58	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	0.6	0
59	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
60	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	0.6	3
61	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
62	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
63	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
64	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 1-1.	0.6	0
65	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
66	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 16-17.	0.6	1
67	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
68	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 50-51.	0.6	7
69	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	2.8	9
70	Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). <i>Acta Haematologica</i> , 2019, 142, 224-232.	0.7	6
71	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 688-698.	0.6	26
72	Ibrutinib + Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	13.9	545

#	ARTICLE	IF	CITATIONS
73	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	0.6	42
74	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. <i>Oncotarget</i> , 2019, 10, 60-75.	0.8	6
75	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	3.3	21
76	B-cell prolymphocytic leukemia has 3 subsets. <i>Blood</i> , 2019, 134, 1777-1778.	0.6	2
77	<i>t</i> (12)(p11.1;p13.1) translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019, 94, 338-345.	2.0	19
78	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. <i>Blood</i> , 2019, 133, 697-709.	0.6	408
79	Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2019, 33, 638-652.	3.3	21
80	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 865-865.	0.6	12
81	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. <i>Blood</i> , 2019, 134, 53-53.	0.6	2
82	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019, 134, 4306-4306.	0.6	3
83	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 679-679.	0.6	1
84	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019, 134, 3050-3050.	0.6	3
85	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	0.6	29
86	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated CARTs. <i>Blood</i> , 2019, 134, 3868-3868.	0.6	6
87	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. <i>Blood</i> , 2019, 134, 2859-2859.	0.6	9
88	Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 7525-7525.	0.8	2
89	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019, 134, 3022-3022.	0.6	0
90	A Role for TNF- α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. <i>Blood</i> , 2019, 134, 4276-4276.	0.6	0

#	ARTICLE	IF	CITATIONS
91	β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance. <i>Blood</i> , 2019, 134, 1739-1739.	0.6	0
92	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 852-852.	0.6	0
93	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019, 134, 3037-3037.	0.6	0
94	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018, 103, e237-e240.	1.7	15
95	Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 337-349.	1.0	11
96	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018, 131, 2541-2551.	0.6	21
97	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect ^Â CLL cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 2327-2335.	0.6	5
98	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 114-124.e2.	0.2	23
99	Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. <i>Blood</i> , 2018, 131, 365-368.	0.6	13
100	Predictive value of the <sc>CLL</sc>â€<sc>IPI</sc> in <sc>CLL</sc> patients receiving chemoâ€immunotherapy as firstâ€line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8
101	Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1612-1624.	1.8	34
102	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427.	1.2	37
103	A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). <i>Blood</i> , 2018, 132, 1BA-4-1BA-4.	0.6	48
104	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. <i>Blood</i> , 2018, 132, 961-961.	0.6	3
105	Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>Blood</i> , 2018, 132, 728-728.	0.6	1
106	Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial. <i>Blood</i> , 2018, 132, 236-236.	0.6	7
107	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. <i>Blood</i> , 2018, 132, 1833-1833.	0.6	0
108	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018, 132, 3116-3116.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions. <i>Blood</i> , 2018, 132, 1865-1865.	0.6	0
110	Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance. <i>Blood</i> , 2018, 132, 3125-3125.	0.6	0
111	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018, 132, 1857-1857.	0.6	0
112	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	0.6	2
113	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	0.6	1
114	Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment. <i>Blood</i> , 2018, 132, 3132-3132.	0.6	0
115	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	0.6	0
116	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. <i>Blood</i> , 2018, 132, 4394-4394.	0.6	0
117	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018, 132, 5538-5538.	0.6	0
118	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335
119	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017, 92, E164-E166.	2.0	5
120	Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. <i>American Journal of Hematology</i> , 2017, 92, 759-763.	2.0	25
121	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e22-e25.	1.7	11
122	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 178, 99-105.	1.2	23
123	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	1.2	66
124	How I treat autoimmune hemolytic anemia. <i>Blood</i> , 2017, 129, 2971-2979.	0.6	134
125	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	2.0	13
126	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 1376-1383.	0.6	33

#	ARTICLE	IF	CITATIONS
127	SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells. <i>British Journal of Haematology</i> , 2017, 178, 155-158.	1.2	13
128	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017, 58, 1630-1639.	0.6	102
129	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 2433-2443.	2.5	12
130	Reply to S. Opat et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 4094-4095.	0.8	1
131	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 2989-2992.	0.8	10
132	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017, 130, 831-831.	0.6	3
133	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. <i>Blood</i> , 2017, 130, 927-927.	0.6	0
134	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <i>American Journal of Hematology</i> , 2016, 91, 687-691.	2.0	20
135	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	0.6	102
136	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 2409-2416.	0.6	12
137	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016, 91, 1090-1095.	2.0	58
138	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e407-e414.	2.2	16
139	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016, 175, 892-903.	1.2	42
140	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
141	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 677-680.	2.0	14
142	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	0.6	4
143	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. <i>Blood</i> , 2016, 128, 2451-2451.	0.6	1
144	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. <i>Blood</i> , 2016, 128, 4364-4364.	0.6	1

#	ARTICLE	IF	CITATIONS
145	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	0.6	8
146	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016, 128, 4772-4772.	0.6	4
147	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 968-968.	0.6	4
148	A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 78269-78280.	0.8	7
149	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016, 128, 2020-2020.	0.6	1
150	Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group. <i>Blood</i> , 2016, 128, 4373-4373.	0.6	0
151	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016, 128, 5585-5585.	0.6	0
152	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016, 128, 5575-5575.	0.6	0
153	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the ConnectA® CLL Registry. <i>Blood</i> , 2016, 128, 5941-5941.	0.6	0
154	Epigenetic Silencing of Catalase Induces Accumulation of Reactive Oxygen Species in Chronic Lymphocytic Leukemia B Cells Leading to Activation of Axl: An Escape Strategy?. <i>Blood</i> , 2016, 128, 4363-4363.	0.6	0
155	Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.. <i>Blood</i> , 2016, 128, 2013-2013.	0.6	0
156	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016, 128, 3228-3228.	0.6	0
157	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016, 128, 5592-5592.	0.6	1
158	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 492-498.	0.6	47
159	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	0.6	83
160	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015, 121, 2883-2891.	2.0	77
161	<sc>H</sc>odgkin transformation of chronic lymphocytic leukemia: <sc>I</sc>ncidence, outcomes, and comparison to <i>de novo</i> <sc>H</sc>odgkin lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 334-338.	2.0	69
162	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 2115-2126.	3.2	59

#	ARTICLE	IF	CITATIONS
163	Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels. <i>Journal of Oncology Practice</i> , 2015, 11, 252-258.	2.5	92
164	Identification of recurrent truncated <i>DDX3X</i> mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 169, 445-448.	1.2	54
165	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. <i>EBioMedicine</i> , 2015, 2, 572-582.	2.7	43
166	Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2303-2312.	1.9	32
167	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015, 100, 1180-1188.	1.7	70
168	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1713-1713.	0.6	1
169	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. <i>Blood</i> , 2015, 126, 2935-2935.	0.6	18
170	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2950-2950.	0.6	5
171	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. <i>Blood</i> , 2015, 126, 4169-4169.	0.6	3
172	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. <i>Blood</i> , 2015, 126, 5265-5265.	0.6	4
173	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. <i>Blood</i> , 2015, 126, 717-717.	0.6	8
174	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	0.6	17
175	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2926-2926.	0.6	0
176	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL [®] Cohort Study. <i>Blood</i> , 2015, 126, 3284-3284.	0.6	0
177	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2015, 126, 2930-2930.	0.6	0
178	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL [®] Registry. <i>Blood</i> , 2015, 126, 4483-4483.	0.6	0
179	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. <i>Blood</i> , 2015, 126, 5264-5264.	0.6	0
180	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL [®] Registry. <i>Blood</i> , 2015, 126, 5270-5270.	0.6	0

#	ARTICLE	IF	CITATIONS
181	A novel method for analysis of human T cell repertoires by real-time PCR. <i>Journal of Immunological Methods</i> , 2014, 412, 24-34.	0.6	1
182	<scp>Akt</scp> inhibitor <scp>MK</scp>2206 selectively targets <scp>CLL B</scp>â€cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce <scp>CLL</scp> apoptosis. <i>British Journal of Haematology</i> , 2014, 164, 146-150.	1.2	19
183	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. <i>Leukemia and Lymphoma</i> , 2014, 55, 2778-2784.	0.6	36
184	Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012. <i>Leukemia Research</i> , 2014, 38, 299-303.	0.4	38
185	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014, 207, 19-30.	0.2	5
186	How we treat Richter syndrome. <i>Blood</i> , 2014, 123, 1647-1657.	0.6	145
187	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 49-62.	0.6	244
188	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
189	Incidence of chronic lymphocytic leukemia and highâ€count monoclonal Bâ€cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014, 120, 2000-2005.	2.0	33
190	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 42-48.	0.6	60
191	Critical Signal Transduction Pathways in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 215-239.	0.8	9
192	CGH Protocols: Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2013, 973, 87-98.	0.4	3
193	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
194	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Leukemia and Lymphoma</i> , 2013, 54, 476-482.	0.6	10
195	Diffuse large <scp>B</scp>â€cell lymphoma (<scp>R</scp>ichter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	1.2	187
196	Ofatumumabâ€based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). <i>Cancer</i> , 2013, 119, 3788-3796.	2.0	41
197	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2013, 121, 4137-4141.	0.6	79
198	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 1891-1899.	0.6	184

#	ARTICLE	IF	CITATIONS
199	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE, 2013, 8, e83830.	1.1	80
200	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. Blood, 2013, 122, 1642-1642.	0.6	5
201	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. Blood, 2013, 122, 4178-4178.	0.6	2
202	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. Blood, 2013, 122, 4179-4179.	0.6	4
203	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2855-2855.	0.6	0
204	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375.	0.6	0
205	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087) Tj ETQq1 1 0.784314 0.6 BT /Over	0.6	0
206	Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. Clinical Advances in Hematology and Oncology, 2013, 11, 720-9.	0.3	13
207	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood, 2012, 120, 843-846.	0.6	76
208	Predicting Clinical Outcome in B-Chronic Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 394-398.	1.8	1
209	Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer, 2012, 118, 1827-1837.	2.0	38
210	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2012, 30, 2483-2491.	0.8	120
211	Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production. Blood, 2012, 120, 3928-3928.	0.6	0
212	Very High Risk CLL Characterized by a "Double Hit" Clone with Both 11q22 and 17p13 Deletion.. Blood, 2012, 120, 2486-2486.	0.6	0
213	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. Blood, 2012, 120, 2877-2877.	0.6	1
214	Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy. Blood, 2012, 120, 3927-3927.	0.6	0
215	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. Blood, 2012, 120, 2893-2893.	0.6	0
216	Clonal Chromosomal Anomalies Similar to CLL and Other Hematologic Malignancies Can Be Found in "Normal" Individuals. Blood, 2012, 120, 873-873.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Extramedullary Chronic Lymphocytic Leukemia: Systematic Analysis of Cases Reported Between 1975 and 2010. <i>Blood</i> , 2012, 120, 4607-4607.	0.6	0
218	Chronic Lymphocytic Leukemia in Young (≤ 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes. <i>Blood</i> , 2012, 120, 2901-2901.	0.6	0
219	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012, 120, 3865-3865.	0.6	0
220	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6	0.6	0
221	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012, 120, 4252-4252.	0.6	0
222	The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. <i>Blood</i> , 2011, 117, 1928-1937.	0.6	109
223	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
224	Bone marrow stromal cells protect lymphoma B cells from rituximab-induced apoptosis and targeting integrin $\alpha 4 \beta 1$ (VLA-4) with natalizumab can overcome this resistance. <i>British Journal of Haematology</i> , 2011, 155, 53-64.	1.2	99
225	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <i>Leukemia and Lymphoma</i> , 2011, 52, 374-386.	0.6	1
226	The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S4087.	0.6	8
227	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011, 52, 1425-1434.	0.6	12
228	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). <i>Blood</i> , 2011, 118, 1790-1790.	0.6	1
229	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011, 118, 2836-2836.	0.6	1
230	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011, 118, 288-288.	0.6	3
231	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. <i>Blood</i> , 2011, 118, 3899-3899.	0.6	2
232	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 799-799.	0.6	1
233	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. <i>Blood</i> , 2011, 118, 2838-2838.	0.6	0
234	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients. <i>Blood</i> , 2011, 118, 3903-3903.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Global Genomic Status At Diagnosis Informs Clinical Outcome in B-Chronic Lymphocytic Leukemia: Stable Versus Progressive Disease. <i>Blood</i> , 2011, 118, 1772-1772.	0.6	0
236	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,. <i>Blood</i> , 2011, 118, 3898-3898.	0.6	1
237	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. <i>Blood</i> , 2011, 118, 3881-3881.	0.6	0
238	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011, 118, 4152-4152.	0.6	1
239	TRIS (DIBENZYLIDENEACETONE) Dipalladium a Small-Molecule Palladium Complex Is Effective in the Induction of Apoptosis for B-Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2011, 118, 2851-2851.	0.6	1
240	Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,. <i>Blood</i> , 2011, 118, 3882-3882.	0.6	0
241	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 2085-2085.	0.6	3
242	Mesenchymal Stromal Cells Derived From Chronic Lymphocytic Leukemic Patients Express Different Genes and Produce Different Cytokines Compared to MSC Derived From Normal Subjects,. <i>Blood</i> , 2011, 118, 3872-3872.	0.6	0
243	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011, 118, 4610-4610.	0.6	0
244	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. <i>Blood</i> , 2011, 118, 3538-3538.	0.6	16
245	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 95-113.	0.4	37
246	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. <i>Blood</i> , 2010, 115, 1755-1764.	0.6	208
247	LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. <i>Blood</i> , 2010, 116, 2975-2983.	0.6	136
248	Platelet-derived growth factor (PDGF)â€“PDGF receptor interaction activates bone marrowâ€“derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. <i>Blood</i> , 2010, 116, 2984-2993.	0.6	113
249	Pentostatin and rituximab therapy for previously untreated patients with Bâ€“cell chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 2180-2187.	2.0	32
250	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 4777-4787.	2.0	107
251	Common occurrence of monoclonal Bâ€“cell lymphocytosis among members of highâ€“risk CLL families. <i>British Journal of Haematology</i> , 2010, 151, 152-158.	1.2	61
252	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 161-168.	1.0	35

#	ARTICLE	IF	CITATIONS
253	Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 47-59.	0.7	84
254	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 620-627.	0.6	59
255	Circulating endothelial cells in chronic lymphocytic leukemia: more evidence of disturbed angiogenesis. <i>Leukemia and Lymphoma</i> , 2009, 50, 8-9.	0.6	2
256	N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 588-592.	0.6	13
257	Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 3959-3963.	0.8	123
258	Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG. <i>Clinical Cancer Research</i> , 2009, 15, 1250-1258.	3.2	114
259	Reply to R.S. Go. <i>Journal of Clinical Oncology</i> , 2009, 27, e45-e45.	0.8	1
260	Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. <i>Epigenomics</i> , 2009, 1, 39-61.	1.0	57
261	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009, 115, 363-372.	2.0	72
262	Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 146, 660-664.	1.2	14
263	Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. <i>British Journal of Haematology</i> , 2009, 147, 471-483.	1.2	74
264	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1261-1268.	0.6	69
265	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. <i>Blood</i> , 2009, 114, 4441-4450.	0.6	284
266	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. <i>Blood</i> , 2009, 113, 535-537.	0.6	61
267	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009, 113, 4188-4196.	0.6	104
268	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. <i>Blood</i> , 2009, 113, 5568-5574.	0.6	129
269	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. <i>Blood</i> , 2009, 114, 957-964.	0.6	150
270	Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.. <i>Blood</i> , 2009, 114, 1265-1265.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Aberrant Regulation of the LEF-1 Locus in Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): A Possible Role for Epigenetic Regulation.. Blood, 2009, 114, 669-669.	0.6	2
272	Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients.. Blood, 2009, 114, 1245-1245.	0.6	0
273	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer, 2008, 113, 2110-2118.	2.0	67
274	Controversies in the front-line management of chronic lymphocytic leukemia. Leukemia Research, 2008, 32, 679-688.	0.4	10
275	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. British Journal of Haematology, 2008, 140, 537-546.	1.2	152
276	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. British Journal of Haematology, 2008, 141, 615-621.	1.2	101
277	Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence. Diagnostic Pathology, 2008, 3, 16.	0.9	37
278	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2008, 49, 49-56.	0.6	176
279	Usefulness of Risk Stratification in the Treatment of Patients with Chronic Lymphocytic Leukemia. Clinical Leukemia, 2008, 2, 46-54.	0.2	0
280	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 2008, 112, 1923-1930.	0.6	282
281	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. Blood, 2008, 112, 2065-2065.	0.6	1
282	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. Blood, 2008, 112, 3125-3125.	0.6	2
283	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. Blood, 2008, 112, 3144-3144.	0.6	2
284	Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy. Blood, 2008, 112, 43-43.	0.6	5
285	Platelet-Derived Growth Factor (PDGF) Secreted by Chronic Lymphocytic Leukemic B-Cells Is Capable of Regulating the Activation and Function of Mesenchymal Stem Cells: Implications for Leukemic Cell/Stromal Cell Crosstalk. Blood, 2008, 112, 355-355.	0.6	0
286	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. Blood, 2008, 112, 3124-3124.	0.6	2
287	De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson/Mayo Clinic Experience.. Blood, 2008, 112, 1056-1056.	0.6	1
288	Overexpression of the LEF-1 and TCF4 Transcription Factors in B-CLL: Further Evidence for a Role of the Wnt Signaling Pathway in B-CLL Biology and Leukemogenesis. Blood, 2008, 112, 544-544.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.. Blood, 2008, 112, 1067-1067.	0.6	0
290	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. Blood, 2008, 112, 3771-3771.	0.6	0
291	<i>Letter to the Editor:</i> Community-Based Phase II Trial of PCR for CLL/SLL Patients. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 713-714.	0.7	6
292	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood, 2007, 109, 405-411.	0.6	278
293	Combination therapies for previously untreated CLL. Lancet, The, 2007, 370, 197-198.	6.3	3
294	Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leukemia and Lymphoma, 2007, 48, 2412-2417.	0.6	85
295	Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer, 2007, 109, 2291-2298.	2.0	145
296	Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leukemia Research, 2007, 31, 899-906.	0.4	67
297	Angiogenesis revisited in CLL. Leukemia Research, 2007, 31, 1459-1460.	0.4	6
298	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research, 2007, 31, 1737-1740.	0.4	14
299	Prognostic factors in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 49-55.	1.2	12
300	Chronic lymphocytic leukemia: Biology and current treatment. Current Oncology Reports, 2007, 9, 345-352.	1.8	10
301	Comprehensive Management of the CLL Patient: A Holistic Approach. Hematology American Society of Hematology Education Program, 2007, 2007, 324-331.	0.9	14
302	Comprehensive Management of the CLL Patient: A Holistic Approach. Hematology American Society of Hematology Education Program, 2007, 2007, 324-331.	0.9	1
303	Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 2050-2050.	0.6	1
304	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. Blood, 2007, 110, 337-337.	0.6	1
305	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. Blood, 2007, 110, 746-746.	0.6	0
306	Dietary Products Induce Apoptosis in CLL B Cells and Reveal Potential as a Therapeutic Combination That Can Overcome Stromal Cell Mediated Protection.. Blood, 2007, 110, 3130-3130.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Characterization of Microvesicles in B-Cell Chronic Lymphocytic Leukemia (CLL): A Potential Mediator in CLL B Cell Disease Progression?.. Blood, 2007, 110, 747-747.	0.6	0
308	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. Blood, 2007, 110, 2615-2615.	0.6	0
309	T-cell abnormalities in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2006, 47, 1197-1198.	0.6	4
310	Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 4634-4641.	0.8	223
311	Purine Analogue-Based Chemotherapy Regimens for Patients With Previously Untreated B-Chronic Lymphocytic Leukemia. Seminars in Hematology, 2006, 43, S50-S54.	1.8	14
312	Loss of TP53 is due to rearrangements involving chromosome region 17p10 ^{1/4} p12 in chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 167, 177-181.	1.0	35
313	The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 174-185.	0.8	47
314	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. Blood, 2006, 108, 234-234.	0.6	2
315	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. Blood, 2006, 108, 2785-2785.	0.6	1
316	Alemtuzumab and Rituximab for Therapy of Patients with Early Stage High Risk CLL: Report of a Planned Interim Analysis.. Blood, 2006, 108, 2829-2829.	0.6	4
317	The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial.. Blood, 2006, 108, 36-36.	0.6	3
318	Elevated HIF-1 β Levels in CLL B Cells May Explain Their Autocrine VEGF Secretion.. Blood, 2006, 108, 583-583.	0.6	0
319	Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NF κ B Nuclear Activity.. Blood, 2006, 108, 2797-2797.	0.6	0
320	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2006, 108, 817-817.	0.6	0
321	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. Blood, 2006, 108, 586-586.	0.6	0
322	Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes.. Blood, 2006, 108, 934-934.	0.6	0
323	D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmutated B-CLL.. Blood, 2006, 108, 2779-2779.	0.6	0
324	Chronic lymphocytic leukemia: current and emerging treatment approaches. Clinical Advances in Hematology and Oncology, 2006, 4, 1-10; quiz 11-2.	0.3	8

#	ARTICLE	IF	CITATIONS
325	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , 2005, 105, 2099-2106.	0.6	40
326	A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. <i>Leukemia Research</i> , 2005, 29, 1009-1018.	0.4	13
327	Diagnostic criteria for monoclonal B-cell lymphocytosis. <i>British Journal of Haematology</i> , 2005, 130, 325-332.	1.2	360
328	MBL and MoBL - Response to Ziegler-Heitbrock. <i>British Journal of Haematology</i> , 2005, 130, 795-796.	1.2	3
329	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. <i>Blood</i> , 2005, 106, 2098-2098.	0.6	3
330	Hypoxia Inducible Factor-1 α Is over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.. <i>Blood</i> , 2005, 106, 2115-2115.	0.6	2
331	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005, 106, 707-707.	0.6	14
332	Tumor Cells Resistant to Alemtuzumab Complement Mediated Cytotoxicity in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure.. <i>Blood</i> , 2005, 106, 2973-2973.	0.6	1
333	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 4758-4758.	0.6	1
334	Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005, 106, 3255-3255.	0.6	0
335	Molecular and Clinical Analysis of a Midwest Cohort of B-CLL Patients Utilizing the Immunoglobulin VH 1-69 Gene.. <i>Blood</i> , 2005, 106, 5016-5016.	0.6	0
336	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 5420-5420.	0.6	0
337	Targeting V α -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V α -4 Therapy.. <i>Blood</i> , 2005, 106, 1182-1182.	0.6	0
338	Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005, 106, 3278-3278.	0.6	0
339	Pentostatin, Chlorambucil and Prednisone Therapy for B-Chronic Lymphocytic Leukemia: A Phase I/II Study by the Eastern Cooperative Oncology Group Study E1488. <i>Leukemia and Lymphoma</i> , 2004, 45, 79-84.	0.6	34
340	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. <i>Blood</i> , 2004, 103, 1202-1210.	0.6	214
341	ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 893-901.	13.9	824
342	VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004, 104, 788-794.	0.6	195

#	ARTICLE	IF	CITATIONS
343	Pathogenesis of Impaired Cellular Immune Function in CLL. , 2004, , 109-121.		7
344	ZAP-70 Expression Associated with Activation in Normal Human B Cells and B Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2794-2794.	0.6	11
345	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 339-339.	0.6	18
346	Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.. Blood, 2004, 104, 1909-1909.	0.6	4
347	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. Blood, 2004, 104, 1475-1475.	0.6	0
348	CLL B Cell Interaction with Bone Biopsy Generated Marrow Stromal Elements Enhances Their Apoptosis Resistance in Association with an Angiogenic Switch.. Blood, 2004, 104, 1914-1914.	0.6	1
349	Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.. Blood, 2004, 104, 964-964.	0.6	0
350	Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes.. Blood, 2004, 104, 4809-4809.	0.6	1
351	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 2003, 121, 287-295.	1.2	198
352	IL-4 Biology: Impact on Normal and Leukemic CLL B Cells. Leukemia and Lymphoma, 2003, 44, 897-903.	0.6	39
353	Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Molecular Cancer Research, 2003, 1, 346-61.	1.5	108
354	Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2002, 2002, 193-213.	0.9	86
355	Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood, 2001, 98, 23-28.	0.6	94
356	Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. British Journal of Haematology, 2001, 112, 760-767.	1.2	48
357	Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 115, 854-861.	1.2	179
358	Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression. Journal of Clinical Immunology, 1999, 19, 239-246.	2.0	5
359	The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Cancer, 1999, 86, 957-968.	2.0	51
360	T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. British Journal of Haematology, 1998, 100, 459-463.	1.2	24

#	ARTICLE	IF	CITATIONS
361	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997, 90, 340-345.	0.6	59
362	Analysis of blood Tâ€cell cytokine expression in Bâ€chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic ILâ€4 in resting and activated CD8 T cells. <i>British Journal of Haematology</i> , 1997, 96, 733-735.	1.2	45
363	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. <i>Blood</i> , 1997, 90, 340-345.	0.6	5
364	Tumor Suppressor Genes and Clonal Evolution in B-CLL. <i>Leukemia and Lymphoma</i> , 1995, 18, 41-49.	0.6	15
365	Sequential Phenotyping of Myeloma Patients on Chemotherapy: Persistence of Activated T-cells and Natural Killer Cells. <i>Leukemia and Lymphoma</i> , 1995, 16, 351-354.	0.6	10
366	Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group. <i>American Journal of Hematology</i> , 1988, 29, 152-163.	2.0	389
367	Differential Effect of Hemodialysis Membranes on Human Lymphocyte Natural Killer Function. <i>Artificial Organs</i> , 1987, 11, 165-167.	1.0	18
368	T-Cell Subpopulations in Multiple Myeloma: Correlation with Clinical Disease Status. <i>British Journal of Haematology</i> , 1981, 49, 629-634.	1.2	42